Clowse, M. E. B., Förger, F., Hwang, C., Thorp, J., Dolhain, R. J. E. M., Tubergen, A. V., … Hale, T. W. (2017). FRI0179 Minimal to no transfer of certolizumab pegol into breast milk: results from cradle, a prospective, postmarketing, multicenter, pharmacokinetic study. In Annals of the Rheumatic Diseases (Vol. 76, pp. 548–549). Elsevier BV. https://doi.org/10.1136/annrheumdis-2017-eular.2467

Clowse, M. E. B., F. Förger, C. Hwang, J. Thorp, R. J. E. M. Dolhain, A van Tubergen, L. Shaughnessy, et al. “FRI0179 Minimal to no transfer of certolizumab pegol into breast milk: results from cradle, a prospective, postmarketing, multicenter, pharmacokinetic study.” In Annals of the Rheumatic Diseases, 76:548–49. Elsevier BV, 2017. https://doi.org/10.1136/annrheumdis-2017-eular.2467.

Clowse MEB, Förger F, Hwang C, Thorp J, Dolhain RJEM, Tubergen AV, et al. FRI0179 Minimal to no transfer of certolizumab pegol into breast milk: results from cradle, a prospective, postmarketing, multicenter, pharmacokinetic study. In: Annals of the Rheumatic Diseases. Elsevier BV; 2017. p. 548–9.

Clowse, M. E. B., et al. “FRI0179 Minimal to no transfer of certolizumab pegol into breast milk: results from cradle, a prospective, postmarketing, multicenter, pharmacokinetic study.” Annals of the Rheumatic Diseases, vol. 76, Elsevier BV, 2017, pp. 548–49. Crossref, doi:10.1136/annrheumdis-2017-eular.2467.

Clowse MEB, Förger F, Hwang C, Thorp J, Dolhain RJEM, Tubergen AV, Shaughnessy L, Simpson J, Teil M, Toublanc N, Wang M, Hale TW. FRI0179 Minimal to no transfer of certolizumab pegol into breast milk: results from cradle, a prospective, postmarketing, multicenter, pharmacokinetic study. Annals of the Rheumatic Diseases. Elsevier BV; 2017. p. 548–549.